Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 75,000 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 75,000 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director owned 31,596 shares in the company, valued at $7,109,100. This trade represents a 70.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Trading Up 1.0%

CRL opened at $229.13 on Thursday. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $236.62. The stock has a market cap of $11.04 billion, a PE ratio of -60.94, a PEG ratio of 2.59 and a beta of 1.39. The business has a 50 day moving average of $179.65 and a 200-day moving average of $184.08.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRL has been the topic of several analyst reports. Evercore reiterated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Barclays boosted their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Mizuho set a $192.00 target price on Charles River Laboratories International in a research note on Friday, May 8th. CLSA raised Charles River Laboratories International from a “hold” rating to an “outperform” rating and lifted their target price for the stock from $167.00 to $219.00 in a report on Friday, May 29th. Finally, BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $215.88.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently made changes to their positions in the business. National Bank of Canada FI raised its position in Charles River Laboratories International by 117.7% in the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after acquiring an additional 511,901 shares during the period. Gotham Asset Management LLC grew its position in shares of Charles River Laboratories International by 17.3% during the 3rd quarter. Gotham Asset Management LLC now owns 315,755 shares of the medical research company’s stock valued at $49,403,000 after acquiring an additional 46,594 shares during the period. Contravisory Investment Management Inc. purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth $1,223,000. Nordea Investment Management AB increased its stake in shares of Charles River Laboratories International by 43.6% in the 4th quarter. Nordea Investment Management AB now owns 54,694 shares of the medical research company’s stock worth $10,985,000 after purchasing an additional 16,616 shares in the last quarter. Finally, Confluence Investment Management LLC raised its holdings in Charles River Laboratories International by 10.1% in the 4th quarter. Confluence Investment Management LLC now owns 105,626 shares of the medical research company’s stock worth $21,070,000 after purchasing an additional 9,663 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.